Association between geniquin therapy and the risk of developing periodontal disease in patients with primary Sjögren’s syndrome: A population-based cohort study from Taiwan

• DOI: 10.1371/journal.pone.0305130
• Publication Date: 2024-08-07T17:29:50Z
• Authors: Chun-Yuan Chiu; Da-Yo Yuh; Li-Chyun Yeh; Iau-Jin Lin; Chi-Hsiang Chung; Chung-Hsing Li; Wu-Chien Chien; Gunng-Shinng Chen
• Keywords: Male; Adult; Taiwan; Middle Aged; Cohort Studies; 03 medical and health sciences; Sjogren's Syndrome; 0302 clinical medicine; Risk Factors; Humans; Female; Periodontal Diseases; Research Article; Aged; Proportional Hazards Models

Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease that causes dysfunction of salivation and harmful oral conditions. The association between periodontal (PD) pSS with or without geniquin therapy remains controversial. This study evaluated the risk subsequent development PD in patients. From Taiwan’s National Health Insurance Research Database, we selected control cohort 106,818 patients, followed up from 2000 to 2015, matched (1:4) by age index year 427,272 non-pSS We also analyzed 15,149 patients receiving (cohort 1) 91,669 not 2). After adjusting for confounding factors, multivariate Cox proportional hazards regression analysis was used compare over 15-year follow-up. In cohort, 11,941 (11.2%) developed compared 39,797 (9.3%) cohorts 1 2, 1,914 (12.6%) 10,027 (10.9%) PD. adjusted hazard ratio (HR) 1.165 (95% confidence interval [CI] = 1.147–1.195, p < 0.001) 1.608 CI 1.526–1.702, 0.001). HR treatment 1.843. Patients diagnosed showed an increased developing than pSS, while even higher risks.